The following therapies were recently approved for this breast cancer subtype: elacestrant [58] (in estrogen receptor 1-mutated breast cancer) aleplisib [59,60] (addressing PIK3CA mutations) and poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors, such as talazoparib [61] or olaparib [62] (for patients with germline pathogenic variants of BRCA1 or BRCA2 genes). This evidence concerns the gene PIK3CA and breast carcinoma.